Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies

On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments across its breast cancer and immunology portfolios, clearing Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease. FDA Approves Oral Breast Cancer Combination Wilserdly The FDA approved Wilserdly (giredestrant) plus everolimus for adults with…

Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies

The U.S. Food and Drug Administration recently granted dual approvals to Roche Holdings AG for two therapies targeting breast cancer and chronic kidney disease. The first approval is for Wilserdly, an all-oral combination of giredestrant and everolimus, which has been cleared for use in advanced breast cancer cases. This treatment targets estrogen receptor-positive, HER2-negative, ESR1-mutated breast cancer, often developing resistance to prior endocrine therapy.

Clinical data from the Phase 3 evERA study demonstrated a 62% reduction in disease progression or death compared to standard endocrine therapy following CDK4/6 inhibitor treatment. Additionally, the FDA approved Gazyva/Gazyvaro for primary membranous nephropathy, marking it as the first approved therapy for this autoimmune disease that can lead to kidney failure.

In the MAJESTY study, 36.1% of patients achieved complete proteinuria remission, compared to 5.7% on tacrolimus, with overall remission rates at 50% versus 12.9% in the comparison group. With no new safety signals identified, this FDA approval positions Gazyva/Gazyvaro as a significant advancement in immune-mediated kidney disease treatment.

Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at benzinga.com →

More in Health & Medicine

More from Tuesday 17 November →